Morgan Stanley analyst Patrick Wood raised the firm’s price target on Boston Scientific (BSX) to $130 from $125 and keeps an Overweight rating on the shares. The firm, which updated its model following Q3 results, notes it is making “modest changes” in light of the company’s most recent guidance and long-range targets.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific: Strong Growth Trajectory and Attractive Valuation Drive Buy Rating
- Boston Scientific price target raised to $140 from $135 at UBS
- Boston Scientific price target raised to $125 from $124 at Wells Fargo
- Boston Scientific’s Strong Performance and Promising Outlook Justifies Buy Rating
- Boston Scientific Reports Strong Q3 2025 Results